Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 17, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	204	138	130	69	38	118
Market Cap Growth	6.60%	6.60%	87.08%	83.20%	-68.02%	143.47%
Enterprise Value	174	117	115	82	26	141
Last Close Price	2.61	1.88	1.78	1.37	0.83	3.63
PE Ratio	71.21	47.21	15.62	-	-	-
Forward PE	6.07	3.94	-	60.89	-	-
PS Ratio	3.55	2.59	1.98	1.46	0.99	1.88
PB Ratio	4.58	3.20	3.87	-6.52	-6.28	-4.38
P/TBV Ratio	4.71	3.20	3.87	-	-	-
P/FCF Ratio	27.55	18.73	-	-	-	-
P/OCF Ratio	23.48	15.96	-	-	-	-
EV/Sales Ratio	3.27	2.19	1.75	1.72	0.68	2.24
EV/EBITDA Ratio	33.40	22.35	9.86	-	-	35.08
EV/EBIT Ratio	44.51	29.80	10.98	-	-	51.93
EV/FCF Ratio	23.59	15.79	-	-	-	-
Debt / Equity Ratio	0.13	0.13	0.78	-3.15	-5.54	-2.38
Debt / EBITDA Ratio	0.81	0.81	2.00	-	-	11.94
Debt / FCF Ratio	0.75	0.75	-	-	-	-
Asset Turnover	0.68	0.68	0.93	0.74	0.54	1.11
Inventory Turnover	1.21	1.21	1.28	1.13	1.05	1.02
Quick Ratio	1.49	1.49	1.11	0.84	1.29	0.48
Current Ratio	2.35	2.35	1.54	1.38	1.86	0.64
Return on Equity (ROE)	7.64%	7.64%	72.50%	-	-	-
Return on Assets (ROA)	3.10%	3.10%	9.32%	-12.57%	-18.06%	2.99%
Return on Capital (ROIC)	4.51%	4.51%	15.81%	-32.36%	-39.47%	12.11%
Return on Capital Employed (ROCE)	8.20%	8.20%	26.90%	-	-	-
Earnings Yield	143.96%	2.12%	6.40%	-21.50%	-72.80%	-5.50%
FCF Yield	362.95%	5.34%	-1.90%	-36.92%	-31.00%	-22.59%
Buyback Yield / Dilution	165.80%	1.66%	-70.04%	-9.81%	-51.43%	-96.44%

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q